Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

Phase 2 Unknown 60 enrolled Guangzhou Institute of Respiratory Disease Shanghai Junshi Bioscience Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, single-arm, multi-center, phase II exploratory study that evaluates the efficacy and safety of Toripalimab injection (JS001) combined with Pemetrexed and Anlotinib as a second-line treatment for patients with T790M positive Non-Small Cell Lung Cancer (IIIb / IV ) after Osimertinib resistance.

Timeline

Start: 2020-04-01
Primary completion: 2022-04-01
Completion: 2022-04-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Catequentinib	Small molecule	12 mg	Oral
Subject	Pemetrexed	Small molecule	500 mg/m2	—
Subject	Toripalimab	Monoclonal antibody	240 mg	Intravenous

Indications

No indication recorded.